(Q35603108)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

review article

1 reference

title

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

Thomas Kurt Eigentler

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Claus Garbe

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Ulrich M Caroli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Peter Radny

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

1 December 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

21 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

748-759

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Incidence of and survival from malignant melanoma in Scotland: an epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Increasing incidence of cutaneous melanoma in Queensland, Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Malignant melanoma: prognostic indicators

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Disseminated melanoma--is there a new standard therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Is there a standard for the palliative treatment of melanoma?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

1 reference

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Comparison of the combination of 1, 3-bis(2-chloroethyl)-l-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-l-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Combination chemotherapy in metastatic malignant melanoma.A randomized study of three DTIC-containing combinations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Desmoids in familial adenomatous polyposis are monoclonal proliferations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901280-4

7 January 2021

10.1016/S1470-2045(03)01280-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14662431%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference